Navigation Links
InterMune to Present at Thomas Weisel Partners Healthcare Conference
Date:8/29/2008

BRISBANE, Calif., Aug. 29 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Daniel G. Welch, Chairman, CEO and President of InterMune, will present at the Thomas Weisel Partners Healthcare Conference in Boston on September 4, 2008 at 10:55 a.m. EDT.

To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at http://www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a research and development portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Former InterMune CEO W. Scott Harkonen Indicted for Wire Fraud and FDA Violations
2. InterMune to Present at the 2008 Wachovia Healthcare Conference
3. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
4. ISTA Pharmaceuticals to Present at the Thomas Weisel Partners Healthcare Conference 2008
5. Zimmer Holdings to Present at Thomas Weisel Partners Conference
6. Aflac Incorporated To Present at the Keefe, Bruyette & Woods 2008 Insurance Conference
7. AMICAS to Present at Thomas Weisel Partners Healthcare Conference 2008
8. HMS Holdings Corp. to Present at Thomas Weisel Partners 2008 Healthcare Conference
9. iCAD to Present at Thomas Weisel Partners Healthcare Conference
10. Stryker to Present at Investor Conferences
11. NxStage Announces Presentation of Data at the American Society of Nephrologys Renal Week 2008 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... LabRoots ... scientists from around the world, announces the launch of its newly redesigned website. ... portal to research breakthroughs and trending news, vital information on upcoming virtual events ...
(Date:1/19/2017)... ... , ... Cosmetic Town, an online plastic surgery community, begins 2017 with an ... for their readers to get the information they desire. The procedures are now listed ... used on those particular areas. , “We are excited to streamline our listings in ...
(Date:1/19/2017)... NJ (PRWEB) , ... January 19, 2017 , ... ... certified dermatologist by the American Board of Dermatology and fellowship trained Mohs and ... the National Institutes of Health, Dr. Li completed his internship in internal medicine ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... doctor who administered fillers that resulted in severe facial disfiguration. After four frightening ... on by doctors at UCLA Medical Center, who removed the substances in a ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... and privacy panel system. , The Tranquility privacy panel system was designed ... office environment. Tranquility panels help reduce noise and provide the visual privacy required ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, Sympathomimetic-GABA Receptor ... market is expected to grow at a CAGR of 27.1% ... 38.7% in the second half of the forecast period. The market ... to 2027. The market is estimated at $1,058 million in 2016, ... ...
(Date:1/19/2017)... RATON, Fla. , Jan. 19, 2017 /PRNewswire/ ... a medical device company specializing in the treatment ... such as keloids, with superficial radiation therapy, today ... and full year 2016 financial results on Thursday, February ... The Company will hold a conference call with ...
(Date:1/19/2017)... January 19, 2017 New ... to Address Motor Symptoms and Motor Complications in ... ...      (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO) C ... European Neurological Review,2016;11(Suppl. 2): 2-15, http://www.touchneurology.com/articles/safinamide-new-therapeutic-option-address-motor-symptoms-and-motor-complications-mid-late ...
Breaking Medicine Technology: